Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | BHMT | Q93088 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259101 | 0.98 | KMT2A (0.37) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL996039 | 0.98 | KMT2A (0.37) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL416894 | 0.98 | KMT2A (0.37) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Hydrochloric Acid SCHEMBL4678546 | 0.95 | KMT2A (0.36) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Hydrochloric Acid SCHEMBL30466615 | 0.95 | KMT2A (0.36) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Hydrochloric Acid SCHEMBL4678540 | 0.95 | KMT2A (0.36) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL28364770 | 0.88 | KIF11 (0.33) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL29069491 | 0.84 | BHMT (0.35) | TDP1KMT2ASMN1; SMN2BHMTSLC1A1 | |
| SCHEMBL8894673 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2KIF11SLC1A1ALDH1A1 | |
| SCHEMBL16775785 | 0.79 | ALDH1A1 (0.40) | TDP1KMT2ASMN1; SMN2KIF11SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734252-B1 | VINCA-ALKALOID VESICLES WITH ENHANCED EFFICACY AND TUMOR TARGETING PROPERTIES | NEXSTAR PHARMACEUTICALS INC (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6120800-A | TO CONTROL DELIVERY OF ENCAPSULATED ANTICANCER AGENTS TO TUMORS IN MAMMALS; DECREASED TOXICITY | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-5888537-A | LIPOSOMES COMPRISED OF PHOSPHATIDYL CHOLINE, CHOLESTEROL AND PHOSPHATIDYL GLYCEROL, HAVING INTERNAL AQUEOUS PHASE CONTAINING CATIONIC VINCA ALKALOID AND ANION OF LOW MEMBRANE PERMEABILITY | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5714163-A | COMPRISING DISTEAROYLPHOSPHATIDYL CHOLINE, CHOLESTEROL AND DISTEAROYLPHOSPHATIDYL GLYCEROL | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0734252-A1 | VINCA-ALKALOID VESICLES WITH ENHANCED EFFICACY AND TUMOR TARGETING PROPERTIES | NeXstar Pharmaceuticals, Inc. (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1996000057-A1 | VINCA-ALKALOID VESICLES WITH ENHANCED EFFICACY AND TUMOR TARGETING PROPERTIES | VESTAR, INC. (US) | 1996-01-04 | — | — | WO | disclosed |